Additionally, GLP-1 slows gastric emptying, meaning food remains in the stomach longer, creating prolonged fullness signals that reduce overall caloric intake naturally
Then things took a turn
So, Im excited that retatrutide could be an option for our non-responders with obesity, Low Wang said
These markers measure response
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Back Barany, G, Barany, MJ (27 Sept 2024) 'Foundational contributions of Svetlana Mojsov to the GLP-1 field', Explorations of Drug Science , 2, 688700